K

P

Pfizer Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

7

Common Fundraising Type

Series B

T
TRIMTECH Therapeutics

Biotech • Targeted protein degradation

SV Health Investors logo
Cambridge Innovation Capital logo
Pfizer Ventures logo
MP Healthcare Venture Management logo

TRIMTECH Therapeutics is a biotech company developing targeted protein degradation therapeutics for neurodegenerative diseases using TRIMTAC degrader molecules.

Seed
$32M
03/05/2025
Article
N
Normunity

Biotechnology • T cell engager

Samsara BioCapital logo
Regeneron Ventures logo
Pfizer Ventures logo
Osage Venture Partners logo

Normunity is a biotechnology company developing anti-cancer therapies that target novel tumor-specific mechanisms to engage T cells and suppress immune evasion in solid tumors.

Series B
$75M
01/13/2025
Article
T
TRexBio

Biotechnology • Inflammatory Diseases

Delos Capital logo
Avego BioScience Capital logo
SV Health Investors logo
Pfizer Ventures logo

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Series B
$84M
11/13/2024
Article
P
Promise Bio

Biotech • Precision Medicine

Awz Ventures logo
Pfizer logo
AstraZeneca logo

Promise Bio is a biotech company that uses a cloud-based AI platform to identify protein modifications for precision medicine in autoimmune diseases.

Seed
$8.3M
10/23/2024
Article
R
RefleXion Medical

Therapeutic Oncology • Solid Tumor Cancer Treatment

Venrock logo
TPG logo
T.Rowe Price Associates logo
Square Point Capital logo

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Equity
$105M
11/15/2023
Article
R
ReCode Therapeutics

Genetic Medicines • MRNA Therapeutics

Bioluminescence Ventures logo
Solasta Ventures logo
Sanofi Ventures logo
Pfizer Ventures logo

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

Series B
$50M
09/19/2023
Article
N
Nimbus Therapeutics

Computational Drug Discovery • Immunology

SR One logo
GV logo
Atlas Venture logo
SV Health Investors logo

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.

Equity
$210M
09/06/2023
Article